FOLH1 and prostate cancer: Additionally, a pilot study reported on the use of [225Ac]Ac-PSMA-617 as a first-line therapy in chemotherapy-naive patients with advanced prostate cancer, in which good anti-tumor response was observed in 16/17 patients following two or three cycles of [225Ac]Ac-PSMA-617, with 11/17 patients showing complete resolution of all metastatic lesions [56].